- 100% control of Fusarium wilt TR4.
- National State of Emergency declared in Colombia in 2019.
- Fusarium wilt TR4 is existential threat to the $25 billion global banana industry.
MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce the initial Colombia laboratory test results of MustGrow’s mustard-derived organic biopesticide formulation on the disease Fusarium wilt TR4 (“Fusarium wilt TR4”), a devastating pathogen ravaging the $25 billion global banana industry – in the past referred to as the Panama Disease. Testing and reporting was completed via third party independent laboratory CyberAgrot SAS in Colombia using Instituto Colombiano Agropecuario (ICA) official protocols.
Controlling the Fusarium wilt TR4 disease definitively, MustGrow has accomplished a unique feat – a feat MustGrow believes no other agri-science team has achieved. This laboratory work will serve as a beachhead for more advanced testing to be used to achieve registration in Colombia and other leading banana producing countries.
CyberAgrot Study Results:
Using ICA official protocols, all plate samples treated with MustGrow’s natural organic biopesticide showed 100% control of Fusarium wilt TR4. Five different rates were tested, each showing 100% disease control. In comparison, control samples (without MustGrow’s technology) showed Fusarium wilt TR4 was still vibrant and growing. All data was assessed after a 5-day period.
Further testing will determine whether MustGrow’s patented biopesticide technology will control Fusarium wilt TR4 in greenhouse and field settings. Fusarium wilt TR4 is the most destructive banana disease, affecting particularly Cavendish bananas, which are half of all bananas produced globally. Currently, there are no effective treatments for infected banana plantations, with the disease remaining viable in soil for decades and can cause 100% yield loss.
Industry expert and General Manager of CyberAgrot, Alexander Chajin Robles commented, “The CyberAgrot team is very pleased with the recent laboratory results of MustGrow’s mustard-derived product. This work further advances MustGrow towards our shared goal of combating the Panama Disease, which has devastated the Banana Industry in Colombia and across the globe. Eliminating the disease is a national priority for the Colombian government, with the disease now affecting acres in many regions of Colombia. MustGrow’s product achieved 100% control of Fusarium wilt TR4 and we very much look forward to now begin field trials. With further success, we will advance conversations with the Colombian Agriculture regulatory body as well as the Colombian Banana Association, accelerating MustGrow’s product as the only 100% organic solution to a growing crisis. A very exciting opportunity.”
The spread of Fusarium wilt TR4 through banana plantations in South America has prompted Colombia to reportedly declare a National State of Emergency, enacting special measures to stop the disease from spreading, including the preventive eradication of 168 hectares of infected crop. A flurry of media reports has followed, revealing a race to save bananas from extinction after the disease has left a trail of scorched banana plantations in its wake.
MustGrow is a publicly traded (CSE: MGRO) (OTCQB: MGROF) (FSE:0C0) agriculture biotech company focused on providing natural science-based biological solutions for high value crops, including fruits & vegetables. MustGrow has designed and owns a United States EPA-approved natural solution that uses the mustard seed’s natural defence mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada’s PMRA (Pest Management Regulatory Agency) as a biopesticide for high value crops such as in fruit & vegetables. MustGrow has now concentrated a liquid format which it’s calling TerraMG, and with regulatory approval, could be applied through standard drip or spray equipment, improving functionality and performance features.
The Company has approximately 37 million basic common shares issued and outstanding. For further details please visit www.mustgrow.ca.
ON BEHALF OF THE BOARD
Director & CEO
Certain statements included in this press release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.
Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”.
Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow.
These risks are described in more detail in MustGrow’s Prospectus and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities and available at www.sedar.com. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.
This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
© 2020 MustGrow Biologics Corp. All rights reserved.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/69190
News Provided by Newsfile via QuoteMedia